ClearPoint Neuro posts Q3 2026 revenue of $12.1 million, raises full-year outlook

ClearPoint Neuro reported third quarter 2026 results on October 28, 2026, for the period ended September 30, 2026. Total revenue reached $12.1 million, up 36% overall, including the recently acquired IRRAflow Portfolio.¹ Neurosurgery navigation and therapy revenue, covering navigation, laser, drill and IRRAflow products, rose 59% to $5.4 million for the quarter.¹ Capital equipment and software revenue hit a record $1.7 million, up 68%, also helped by the acquired IRRAflow equipment.¹ Biologics and drug delivery revenue increased 11% year over year to $4.9 million.¹

On the pipeline side, the company said one partner submitted the first formal Biologics License Application for the treatment of Huntington's Disease.¹ Separately, ClearPoint said it is an industry partner on a five-year, $2.98 million National Cancer Institute R01 grant led by Dartmouth Health aimed at advancing MR-guided laser therapy for spinal metastases¹, a program that covers work from the bench through large-subject validation and into a clinical trial using the ClearPoint Prism system, with ClearPoint providing technical, software development, and procedural support¹. The company called this early-stage research that supports its spine LITT roadmap.¹

ClearPoint also said it received net proceeds of $22.0 million from its at-the-market equity offering program¹ and reported cash and cash equivalents of $46.2 million as of September 30, 2026.¹ The company said this cash position supports a broad product pipeline spanning AI-based planning and simulation tools, neuro navigation for MRI and operating room settings, laser therapy and access, IRRAflow CSF management, robotic surgery, focused ultrasound, and its drug delivery services business.¹

ClearPoint raised its outlook, saying it now estimates 2026 revenue of between $48.0 million and $50.0 million.¹